About
Immunotherapy
Areas of Focus
Categories
Biologics & Biopharmaceutical
Clinical Trials (7)
View allTotal Trials
7
As Lead Sponsor
6
As Collaborator
1
Total Enrollment
398
By Phase
NA: 2PHASE1/PHASE2: 2PHASE1: 3
By Status
RECRUITING: 2COMPLETED: 2NOT_YET_RECRUITING: 1TERMINATED: 1UNKNOWN: 1
Clinical Trials Pipeline7 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT07181811Lead Sponsor
Assessing the Effects of Ongoing Ocrelizumab (OCR) Therapy on Fatigue and Cognition in Veterans With Multiple Sclerosis
NANot yet recruiting
30 participants
Started: Sep 30, 2025 · Completed: Jun 1, 2028
NCT06470763Lead Sponsor
A Study Evaluating ANV600 Single Agent or in Combination with Pembrolizumab in Participants with Advanced Solid Tumors (EXPAND-1)
PHASE1/PHASE2Recruiting
240 participants
Started: Jul 1, 2024 · Completed: Feb 29, 2028
NCT05869539Collaborator
ACT-TIL and ANV419 for Advanced Melanoma.
PHASE1Recruiting
10 participants
Started: Jun 21, 2023 · Completed: Jun 30, 2025
NCT05641324Lead Sponsor
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
PHASE1Terminated
4 participants
Started: Feb 10, 2023 · Completed: Jul 12, 2023
NCT05578872Lead Sponsor
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
PHASE1/PHASE2Completed
29 participants
Started: Dec 16, 2022 · Completed: Aug 1, 2024
Locations (1)
Headquarters
Basel, Switzerland
Map
Loading map...